Vipul Bhargava
Research Subjects
Vipul Bhargava has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Alice M. Walsh
Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA
1 shared publication - Allison M. W. Malloy
Department of Pediatrics, Uniformed Services University of Health Sciences, Bethesda, USA
1 shared publication - Annie W. Lau-Kilby
Research and Medical Affairs, Amgen Inc , Thousand Oaks, CA
1 shared publication - Barry Moran
School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland
1 shared publication Brad Foulk
Janssen Pharmaceuticals Spring House Pennsylvania
1 shared publication- Carl Orr
Centre for Arthritis and Rheumatic Diseases, Saint Vincent's University Hospital, Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 6 December 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (23)
Enriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis
CD141 + DC are implicated in antiviral and antitumor immunity. However, mechanistic studies in autoimmune disease are limited. This is the first study to our knowledge examining CD141 + DC in autoimmune disease, specifically inflammatory arthritis (IA). We identified significant enrichment of CD141 + DC in the inflamed synovial joint, which were transcriptionally distinct from IA and healthy control (HC) blood CD141 + DC and significantly more activated, and they exhibited increased responsiveness to TLR3. Synovial CD141 + DC represent a bone fide CD141 + DC population that is distinct from CD1c + DC. Synovial CD141 + DC induced higher levels of CD4 + and CD8 + T cell activation compared with their peripheral blood counterparts, as made evident by expression of IFN-γ, TNF-α, and granulocyte-macrophage CSF (GMCSF). Autologous synovial CD141 + DC cocultures also induce higher levels of these cytokines, further highlighting their contribution to synovial inflammation. Synovial CD141 + DC–T cell interactions had the ability to further activate synovial fibroblasts, inducing adhesive and invasive pathogenic mechanisms. Furthermore, we identify a mechanism in which synovial CD141 + DC are activated, via ligation of the hypoxia-inducible immune-amplification receptor TREM-1, which increased synovial CD141 + DC activation, migratory capacity, and proinflammatory cytokines. Thus, synovial CD141 + DC display unique mechanistic and transcriptomic signatures, which are distinguishable from blood CD141 + DC and can contribute to synovial joint inflammation.
- 6 December 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (23)
Open AccessEnriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis
CD141 + DC are implicated in antiviral and antitumor immunity. However, mechanistic studies in autoimmune disease are limited. This is the first study to our knowledge examining CD141 + DC in autoimmune disease, specifically inflammatory arthritis (IA). We identified significant enrichment of CD141 + DC in the inflamed synovial joint, which were transcriptionally distinct from IA and healthy control (HC) blood CD141 + DC and significantly more activated, and they exhibited increased responsiveness to TLR3. Synovial CD141 + DC represent a bone fide CD141 + DC population that is distinct from CD1c + DC. Synovial CD141 + DC induced higher levels of CD4 + and CD8 + T cell activation compared with their peripheral blood counterparts, as made evident by expression of IFN-γ, TNF-α, and granulocyte-macrophage CSF (GMCSF). Autologous synovial CD141 + DC cocultures also induce higher levels of these cytokines, further highlighting their contribution to synovial inflammation. Synovial CD141 + DC–T cell interactions had the ability to further activate synovial fibroblasts, inducing adhesive and invasive pathogenic mechanisms. Furthermore, we identify a mechanism in which synovial CD141 + DC are activated, via ligation of the hypoxia-inducible immune-amplification receptor TREM-1, which increased synovial CD141 + DC activation, migratory capacity, and proinflammatory cytokines. Thus, synovial CD141 + DC display unique mechanistic and transcriptomic signatures, which are distinguishable from blood CD141 + DC and can contribute to synovial joint inflammation.
- Open Access
- 8 February 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (3)
Restoration of the type I IFN–IL-1 balance through targeted blockade of PTGER4 inhibits autoimmunity in NOD mice
Type I IFN (IFN-I) dysregulation contributes to type 1 diabetes (T1D) development, and although increased IFN-I signals are pathogenic at the initiation of autoimmune diabetes, IFN-I dysregulation at later pathogenic stages more relevant for therapeutic intervention is not well understood. We discovered that 5 key antigen-presenting cell subsets from adult prediabetic NOD mice have reduced responsiveness to IFN-I that is dominated by a decrease in the tonic-sensitive subset of IFN-I response genes. Blockade of IFNAR1 in prediabetic NOD mice accelerated diabetes and increased Th1 responses. Therefore, IFN-I responses shift from pathogenic to protective as autoimmunity progresses, consistent with chronic IFN-I exposure. In contrast, IL-1–associated inflammatory pathways were elevated in prediabetic mice. These changes correlated with human T1D onset-associated gene expression. Prostaglandin E2 (PGE2) and prostaglandin receptor 4 (PTGER4), a receptor for PGE2 that mediates both inflammatory and regulatory eicosanoid signaling, were higher in NOD mice and drive innate immune dysregulation. Treating prediabetic NOD mice with a PTGER4 antagonist restored IFNAR signaling, decreased IL-1 signaling, and decreased infiltration of leukocytes into the islets. Therefore, innate cytokine alterations contribute to both T1D-associated inflammation and autoimmune pathogenesis. Modulating innate immune balance via signals such as PTGER4 may contribute to treatments for autoimmunity.
- 8 February 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (3)
Open AccessRestoration of the type I IFN–IL-1 balance through targeted blockade of PTGER4 inhibits autoimmunity in NOD mice
Type I IFN (IFN-I) dysregulation contributes to type 1 diabetes (T1D) development, and although increased IFN-I signals are pathogenic at the initiation of autoimmune diabetes, IFN-I dysregulation at later pathogenic stages more relevant for therapeutic intervention is not well understood. We discovered that 5 key antigen-presenting cell subsets from adult prediabetic NOD mice have reduced responsiveness to IFN-I that is dominated by a decrease in the tonic-sensitive subset of IFN-I response genes. Blockade of IFNAR1 in prediabetic NOD mice accelerated diabetes and increased Th1 responses. Therefore, IFN-I responses shift from pathogenic to protective as autoimmunity progresses, consistent with chronic IFN-I exposure. In contrast, IL-1–associated inflammatory pathways were elevated in prediabetic mice. These changes correlated with human T1D onset-associated gene expression. Prostaglandin E2 (PGE2) and prostaglandin receptor 4 (PTGER4), a receptor for PGE2 that mediates both inflammatory and regulatory eicosanoid signaling, were higher in NOD mice and drive innate immune dysregulation. Treating prediabetic NOD mice with a PTGER4 antagonist restored IFNAR signaling, decreased IL-1 signaling, and decreased infiltration of leukocytes into the islets. Therefore, innate cytokine alterations contribute to both T1D-associated inflammation and autoimmune pathogenesis. Modulating innate immune balance via signals such as PTGER4 may contribute to treatments for autoimmunity.
Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)
BACKGROUND: Two androgen receptor (AR)‐targeted therapies, enzalutamide and abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of metastatic castration‐resistant prostate cancer (CRPC). Many patients respond to these agents, but both de novo and acquired resistance are common. The authors characterized resistant phenotypes that emerge after treatment with abiraterone or enzalutamide.METHODS: Patients who received abiraterone or enzalutamide in the course of routine clinical care were consented for serial blood collection. A proprietary system (CellSearch) was used to enumerate and enrich circulating tumor cells (CTCs). RNA‐sequencing (RNA‐seq) was performed on pools of up to 10 epithelial cell adhesion molecule (EpCAM)‐positive/CD45‐negative CTCs. The impact of gene expression changes observed in CTCs between patients who responded or were resistant to abiraterone/enzalutamide therapies was further explored in a model cell line system.RESULTS: RNA‐seq data from CTCs identified mutations commonly associated with CRPC as well as novel mutations, including several in the ligand‐binding domain of AR that could facilitate escape from AR‐targeted agents. Ingenuity pathway analysis of differentially regulated genes identified the transforming growth factor β (TGFβ) and cyclin D1 (CCND1) signaling pathways as significantly upregulated in drug‐resistant CTCs. Transfection experiments using enzalutamide‐sensitive and enzalutamide‐resistant LNCaP cells confirmed the involvement of SMAD family member 3, a key mediator of the TGFβ pathway, and of CCND1 in resistance to enzalutamide treatment.CONCLUSIONS: The current results indicate that RNA‐seq of CTCs representing abiraterone and enzalutamide sensitive and resistant states can identify potential mechanisms of resistance. Therapies targeting the downstream signaling mediated by SMAD family member 3 (SMAD3) and CCND1, such as cyclin‐dependent kinase 4/cyclin‐dependent kinase 6 inhibitors, could provide new therapeutic options for the treatment of antiandrogen‐resistant disease. Cancer 2018;124:1216‐24. © 2017 American Cancer Society.
Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)
BACKGROUND: Two androgen receptor (AR)‐targeted therapies, enzalutamide and abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of metastatic castration‐resistant prostate cancer (CRPC). Many patients respond to these agents, but both de novo and acquired resistance are common. The authors characterized resistant phenotypes that emerge after treatment with abiraterone or enzalutamide.METHODS: Patients who received abiraterone or enzalutamide in the course of routine clinical care were consented for serial blood collection. A proprietary system (CellSearch) was used to enumerate and enrich circulating tumor cells (CTCs). RNA‐sequencing (RNA‐seq) was performed on pools of up to 10 epithelial cell adhesion molecule (EpCAM)‐positive/CD45‐negative CTCs. The impact of gene expression changes observed in CTCs between patients who responded or were resistant to abiraterone/enzalutamide therapies was further explored in a model cell line system.RESULTS: RNA‐seq data from CTCs identified mutations commonly associated with CRPC as well as novel mutations, including several in the ligand‐binding domain of AR that could facilitate escape from AR‐targeted agents. Ingenuity pathway analysis of differentially regulated genes identified the transforming growth factor β (TGFβ) and cyclin D1 (CCND1) signaling pathways as significantly upregulated in drug‐resistant CTCs. Transfection experiments using enzalutamide‐sensitive and enzalutamide‐resistant LNCaP cells confirmed the involvement of SMAD family member 3, a key mediator of the TGFβ pathway, and of CCND1 in resistance to enzalutamide treatment.CONCLUSIONS: The current results indicate that RNA‐seq of CTCs representing abiraterone and enzalutamide sensitive and resistant states can identify potential mechanisms of resistance. Therapies targeting the downstream signaling mediated by SMAD family member 3 (SMAD3) and CCND1, such as cyclin‐dependent kinase 4/cyclin‐dependent kinase 6 inhibitors, could provide new therapeutic options for the treatment of antiandrogen‐resistant disease. Cancer 2018;124:1216‐24. © 2017 American Cancer Society.